NCT06062745
Pilot Study for Detection of PSMA-Low CRPC-NE Tumors With Fluciclovine PET/CT
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 5 versions: 5 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Primary completion pushed from Sep 1, 2026 to Sep 1, 2027
- Eligibility criteria expanded, about 13 words
- Interventions: 18F-fluciclovine (Drug), PET/CT (Device) to 18F-fluciclovine (Drug), PET/CT (Device)
- Site contacts updated at 1 of 2 sites
- Minor Site contacts updated at 1 of 2 sitesv4
- Minor Site contacts updated at 1 of 2 sitesv3
- Notable Lead sponsor: Dana-Farber Cancer Institute to Brigham and Women's Hospital
- Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Feb 2024 to Feb 1, 2024
- Site details revised at 2 of 2 sites
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Fluciclovine and PSMA Uptake in PSMA Positive Tumors
Timeframe: Up to 6 months
Fluciclovine and PSMA Uptake in PSMA Negative Tumors
Timeframe: up to 6 months
Arms and interventions
18F-fluciclovineExperimental
Participants with low prostate-specific membrane antigen (PSMA) expression or neuroendocrine prostate cancer will receive: * 18F-fluciclovine PET/CT within 6 weeks of standard of care exam and 68Ga-PSMA PET/CT * 2x Blood test at time of 18F-fluciclovine PET/CT and prior to treatment as determined by participants primary oncologist
Drugs: 18F-fluciclovine
Devices: PET/CT
Sites
2 sites in 1 country